semaglutide hold before surgery New Study Recommends Stopping GLP-1 Agonists 14 Days Total Joint Arthroplasty to Reduce Anesthesia Risks Health Rounds: No need to

Combination Approaches Future treatments might combine incretin agonists with other weight loss mechanisms like metabolism boosters, appetite suppressants working through non-incretin pathways, or fat absorption inhibitors

FDA approves first treatment to reduce risk of serious heart problems in adults with obesity

Excessive weight has also become a social issue, causing those who are obese to reach out for any weight loss help they can getwhether or not it is right for them

The key regulatory milestones: FDA Breakthrough Therapy designation for MASH (September 2024) EMA PRIME designation for MASH (November 2023) China NMPA Breakthrough designation (June 2024) Phase 3 trials (SYNCHRONIZE-1 and SYNCHRONIZE-2) fully enrolled, results expected H1 of this year Estimated FDA filing: Late this year at the earliest Estimated FDA approval: Possibly next year, depending on Phase 3 results If Phase 3 results confirm Phase 2 findings, survodutide could reach the market within the next 12-24 months

How about taking it properly under the supervision of an expert healthcare provider